Exact Tests for the Analysis of Case-Control Studies of Genetic Markers

2002 ◽  
Vol 54 (3) ◽  
pp. 151-156 ◽  
Author(s):  
Markus Neuhäuser
Keyword(s):  
Genetic Markers ◽  
Case Control ◽  
Exact Tests ◽  
Case Control Studies

Combining Association Tests across Multiple Genetic Markers in Case-Control Studies

2008 ◽  
Vol 65 (3) ◽  
pp. 166-174 ◽  
Author(s):  
Huanyu Zhou ◽  
Lee-Jen Wei ◽  
Xiping Xu ◽  
Xin Xu
Keyword(s):  
Genetic Markers ◽  
Case Control ◽  
Case Control Studies ◽  
Association Tests

Trend Tests for Case-Control Studies of Genetic Markers: Power, Sample Size and Robustness

2002 ◽  
Vol 53 (3) ◽  
pp. 146-152 ◽  
Author(s):  
Boris Freidlin ◽  
Gang Zheng ◽  
Zhaohai Li ◽  
Joseph L. Gastwirth
Keyword(s):  
Sample Size ◽  
Genetic Markers ◽  
Case Control ◽  
Case Control Studies

Case-Control Studies

2009 ◽  
Author(s):  
Ruth H. Keogh ◽  
D. R. Cox
Keyword(s):  
Case Control ◽  
Case Control Studies

Clinical Trials in Thrombosis: Secondary Prevention of Myocardial Infarction

1976 ◽  
Vol 35 (01) ◽  
pp. 049-056 ◽  
Author(s):  
Christian R Klimt ◽  
P. H Doub ◽  
Nancy H Doub
Keyword(s):  
Myocardial Infarction ◽  
Secondary Prevention ◽  
Case Control ◽  
Therapeutic Effects ◽  
Case Control Studies ◽  
Definitive Answer ◽  
Inhibition Of Platelet Aggregation ◽  
Prospective Trials

SummaryNumerous in vivo and in vitro experiments, investigating the inhibition of platelet aggregation and the prevention of experimentally-induced thrombosis, suggest that anti-platelet drugs, such as aspirin or the combination of aspirin and dipyridamole or sulfinpyrazone, may be effective anti-thrombotic agents in man. Since 1971, seven randomized prospective trials and two case-control studies have been referenced in the literature or are currently being conducted, which evaluate the effects of aspirin, sulfinpyrazone, or dipyridamole in combination with aspirin in the secondary prevention of myocardial infarction. A critical review of these trials indicates a range of evidence from no difference to a favorable trend that antiplatelet drugs may serve as anti-thrombotic agents in man. To date, a definitive answer concerning the therapeutic effects of these drugs in the secondary prevention of coronary heart disease is not available.

Sign in / Sign up

Export Citation Format

Share Document